摘要:
Disclosed is a process for producing a human thrombopoietin (hTPO)-containing culture fluid, comprising the step of culturing a eukaryotic cell expressing hTPO in a serum-free medium that contains a negligible amount of serum. In addition, the present invention discloses a process for purifying hTPO from a hTPO-containing biological fluid, comprising the steps of (a) subjecting the biological fluid to affinity chromatography; (b) subjecting an eluate obtained at step (a) to hydrophobic interaction chromatography; (c) subjecting an eluate obtained at step (b) to reverse phased chromatography; and (d) subjecting an eluate obtained at step (c) to anion exchange chromatography. In addition, the present invention discloses hTPO with a high sialic acid content obtained by the process which comprises the step of loading, the eluate obtained at step (c) onto an ionic exchange chromatography column and collecting hTPO with a high content of sialic acid eluted selectively from the column by a 0.15-0.3M sodium chloride gradient.
摘要:
The present invention relates to novel human thrombopoietin (hTPO) derivatives, and to process of preparation thereof. Particularly, sugar chains are introduced into native hTPO by substituting amino acids such as asparagine for amino acids at specific positions in native hTPO, preparing novel hTPO derivatives with high activities enhancing the platelet production in vivo. Therefore, the novel hTPO derivatives of this invention may be useful for the treatment of thrombocytopenia associated with anticancer therapy or the transplantation of bone marrow.
摘要:
The present invention relates to novel human thrombopoietin (hTPO) derivatives, and to process of preparation thereof. Particularly, sugar chains are introduced into native hTPO by substituting amino acids such as asparagine for amino acids at specific positions in native hTPO, preparing novel hTPO derivatives with high activities enhancing the platelet production in vivo. Therefore, the novel hTPO derivatives of this invention may be useful for the treatment of thrombocytopenia associated with anticancer therapy or the transplantation of bone marrow.
摘要:
A particulate composition suitable for making color toner includes resin particles optionally containing a charge control agent. The particles are characterized by a micro-serrated surface exhibiting a surface roughness index of at least about 1.2 and preferably higher. A process for making the particulate composition utilizes a vaporizable plasticizer.
摘要:
The present invention relates to a topical composition containing human epidermal growth factor (hEGF) and polyoxyethylene-polyoxypropylene copolymer having a viscosity of 4-10 cps at 37° C, 60 rpm as the base for topical formulation to improve the wound healing ability of hEGF.
摘要:
A particulate toner composition is provided with toner resin particles containing a resin component, a colorant component, and optionally a charge control agent characterized in that the toner resin particles have a micro-serrated surface exhibiting a surface roughness index of greater than about 1.2. The novel toner particles are produced by employing a vaporizable plasticizer which is flashed off during processing.